BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Otezla (apremilast) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Otezla (apremilast)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04227314-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT04227314)
DESCRIPTION:Otezla (apremilast)\, phase 3.\nStudy: Randomized Double Blind 
 Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Pl
 acebo in Severe Forms of Recurrent Aphthous Stomatitis\nEstimated primary 
 completion: December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/apremilast#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04227314
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06593197-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Otezla (apremilast): Phase 4 readout est. (NCT06593197)
DESCRIPTION:Otezla (apremilast)\, phase 4.\nStudy: Efficacy and Safety of A
 premilast in Combination with NBUVB and NBUVB Alone in Vitiligo Patients\n
 Estimated primary completion: 30 December 2026. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/apremilast#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06593197
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398651-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Otezla (apremilast): Phase na readout est. (NCT07398651)
DESCRIPTION:Otezla (apremilast)\, phase na\, Psoriatic Arthritis.\nStudy: A
 premilast and Adalimumab in Psoriatic Arthritis Patients\nEstimated primar
 y completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/apremilast#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07398651
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908641-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270110
DTEND;VALUE=DATE:20270111
SUMMARY:Otezla (apremilast): Phase 1 readout est. (NCT07908641)
DESCRIPTION:Otezla (apremilast)\, phase 1\, Psoriatic Arthritis.\nStudy: Co
 mparing the Extent to Which Apremilast is Made Available in the Body After
  Administration as an Extended-release or Immediate-release Formulation\nE
 stimated primary completion: 10 January 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/apremilast#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07908641
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325266-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Otezla (apremilast): Phase 2 readout est. (NCT07325266)
DESCRIPTION:Otezla (apremilast)\, phase 2.\nStudy: Human Laboratory Study o
 f Apremilast for Alcohol Use Disorder\nEstimated primary completion: 31 Ja
 nuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apremilas
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 325266
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07366268-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Otezla (apremilast): Phase na readout est. (NCT07366268)
DESCRIPTION:Otezla (apremilast)\, phase na\, Psoriasis.\nStudy: Evaluation 
 the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Ps
 oriasis\nEstimated primary completion: May 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/apremilast#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07366268
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04804553-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT04804553)
DESCRIPTION:Otezla (apremilast)\, phase 3\, Psoriatic Arthritis.\nStudy: Ap
 remilast Pediatric Study in Children With Active Juvenile Psoriatic Arthri
 tis\nEstimated primary completion: 21 March 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/apremilast#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04804553
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02735707-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT02735707)
DESCRIPTION:Otezla (apremilast)\, phase 3.\nStudy: Randomized\, Embedded\, 
 Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia\n
 Estimated primary completion: June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/apremilast#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT02735707
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04488081-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Otezla (apremilast): Phase 2 readout est. (NCT04488081)
DESCRIPTION:Otezla (apremilast)\, phase 2.\nStudy: I-SPY COVID-19 TRIAL: An
  Adaptive Platform Trial for Critically Ill Patients\nEstimated primary co
 mpletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/apremilast#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04488081
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05703685-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20281003
DTEND;VALUE=DATE:20281004
SUMMARY:Otezla (apremilast): Phase 1 readout est. (NCT05703685)
DESCRIPTION:Otezla (apremilast)\, phase 1.\nStudy: [18F]PF-06445974 to Imag
 e PDE4B in Major Depressive Disorder Using PET\nEstimated primary completi
 on: 3 October 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 premilast#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05703685
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04528082-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20300207
DTEND;VALUE=DATE:20300208
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT04528082)
DESCRIPTION:Otezla (apremilast)\, phase 3.\nStudy: Apremilast Pediatric Stu
 dy in Children With Active Oral Ulcers Associated With Behçet's Disease\n
 Estimated primary completion: 7 February 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/apremilast#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04528082
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07352566-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Otezla (apremilast): Phase 4 readout est. (NCT07352566)
DESCRIPTION:Otezla (apremilast)\, phase 4\, Psoriasis.\nStudy: Utilization 
 of a Microdevice for Psoriasis and Atopic Dermatitis\nEstimated primary co
 mpletion: 1 June 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/apremilast#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07352566
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029529-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Otezla (apremilast): Phase 2 readout est. (NCT07029529)
DESCRIPTION:Otezla (apremilast)\, phase 2.\nStudy: Phase 2 Study of Apremil
 ast in Women and Men With Alcohol Use Disorder\nEstimated primary completi
 on: August 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apre
 milast#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07029529
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05767047-95@assetmemo.bio
DTSTAMP:20261121T004045Z
DTSTART;VALUE=DATE:20360317
DTEND;VALUE=DATE:20360318
SUMMARY:Otezla (apremilast): Phase 3 readout est. (NCT05767047)
DESCRIPTION:Otezla (apremilast)\, phase 3\, Psoriatic Arthritis.\nStudy: A 
 Study of Apremilast in Children With Oral Ulcers Associated With Behçet's
  Disease or Juvenile Psoriatic Arthritis\nEstimated primary completion: 17
  March 2036. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/apremila
 st#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5767047
URL:https://assetmemo.bio/drug/apremilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
